United Therapeutics’ Q4 Sales Beat, But Stock Takes a Dip: What the Analysts Aren’t Telling You
UTHR’s Surprising Fourth-Quarter Results: A Mixed Bag UTHR, the biotech company that has been making waves in the industry with its innovative treatments, recently reported its fourth-quarter earnings. And the numbers have left investors and analysts with a mix of excitement and disappointment. Earnings Beat Estimates, But… Let’s start with the good news: UTHR managed…